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Phenotypic, Functional, and Gene Expression Profiling
of Peripheral CD45RA1 and CD45RO1
CD41CD251CD127low Treg Cells in Patients With
Chronic Rheumatoid Arthritis
Gina J. Walter,1 Veerle Fleskens,1 Klaus S. Frederiksen,2 Megha Rajasekhar,1 Bina Menon,3
Jens G. Gerwien,2 Hayley G. Evans,1 and Leonie S. Taams1
Objective. Conflicting evidence exists regarding
the suppressive capacity of Treg cells in the peripheral
blood (PB) of patients with rheumatoid arthritis (RA).
The aim of this study was to determine whether Treg
cells are intrinsically defective in RA.
Methods. Using a range of assays on PB samples
from patients with chronic RA and healthy controls,
CD31CD41CD251CD127low Treg cells from the
CD45RO1 or CD45RA1 T cell compartments were ana-
lyzed for phenotype, cytokine expression (ex vivo and
after in vitro stimulation), suppression of Teff cell pro-
liferation and cytokine production, suppression of
monocyte-derived cytokine/chemokine production, and
gene expression profiles.
Results. No differences between RA patients and
healthy controls were observed with regard to the fre-
quency of Treg cells, ex vivo phenotype (CD4, CD25,
CD127, CD39, or CD161), or proinflammatory cytokine
profile (interleukin-17 [IL-17], interferon-g [IFNg], or
tumor necrosis factor [TNF]). FoxP3 expression was
slightly increased in Treg cells from RA patients. The
ability of Treg cells to suppress the proliferation of T cells
or the production of cytokines (IFNg or TNF) upon cocul-
ture with autologous CD45RO1 Teff cells and monocytes
was not significantly different between RA patients and
healthy controls. In PB samples from some RA patients,
CD45RO1 Treg cells showed an impaired ability to sup-
press the production of certain cytokines/chemokines
(IL-1b, IL-1 receptor antagonist, IL-7, CCL3, or CCL4)
by autologous lipopolysaccharide-activated monocytes.
However, this was not observed in all patients, and other
cytokines/chemokines (TNF, IL-6, IL-8, IL-12, IL-15, or
CCL5) were generally suppressed. Finally, gene expres-
sion profiling of CD45RA1 or CD45RO1 Treg cells
from the PB revealed no statistically significant differ-
ences between RA patients and healthy controls.
Conclusion. Our findings indicate that there is
no global defect in either CD45RO1 or CD45RA1 Treg
cells in the PB of patients with chronic RA.
T cells with a regulatory phenotype (i.e., CD41
CD251CD127lowFoxP31) are abundantly present in
the inflamed joints of patients with rheumatoid arthritis
(RA) (1–8). However, despite their presence, inflamma-
tion persists, thus posing the question as to whether
Treg cells are functionally impaired in RA. Evidence
that CD41CD251 Treg cells are important in control-
ling the severity of arthritis comes from experimental
mouse studies in which depletion of Treg cells using an
anti-CD25–depleting antibody before immunization
resulted in exacerbated disease (9,10). Conversely,
adoptive transfer of CD41CD251 Treg cells in the
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early phase of the disease led to a reduction in disease
severity (10,11). Additionally, earlier onset of disease
and more aggressive disease progression were observed
in the K/BxN model of spontaneous arthritis in scurfy
mice, a mouse strain that is devoid of Treg cells due to a
mutation in the Foxp3 gene and, consequently, develops
severe multiorgan inflammation (12). These data sug-
gest that a functional impairment of Treg cells may con-
tribute to chronic joint inflammation.
Indeed, several groups of investigators have
shown that peripheral Treg cell function is defective in
RA patients (13–16). It was reported that Treg cells
from patients with active RA can suppress the prolifera-
tion of Teff cells, but the ability of Treg cells to inhibit
proinflammatory cytokine production, such as produc-
tion of interferon-g (IFNg) and tumor necrosis factor
(TNF) by T cells and production of TNF by monocytes,
is impaired (13). The inability of Treg cells from RA
patients to suppress IFNg production in Teff cells has
also been demonstrated by other groups (15–17). It was
proposed that this functional defect may be caused by
negative effects of TNF on Treg cell function (14,15),
which was supported by the finding that TNF blockade
could improve Treg cell function (13–15,18).
However, results from several studies have contra-
dicted the notion that defective Treg cell function con-
tributes to inflammatory arthritis. In nude mice injected
with CD25-depleted lymphocyte suspensions, relatively
few animals developed signs of polyarthritis under non–
disease-inducing conditions (19,20). In addition, in human
studies, signs of arthritis were observed in only a few cases
of X-linked syndrome of immune dysregulation, polyen-
docrinopathy, and enteropathy (IPEX), a disease that
develops in individuals with a FOXP3 gene mutation
(21,22); instead, patients with IPEX present with throm-
bocytopenia, insulin-dependent diabetes mellitus, diar-
Table 1. Demographic and clinical characteristics of the patients with rheumatoid arthritis (RA) and healthy control
subjects*













Sex, no. female/no. male 38/5 11/2 27/15 11/4 9/3
Age, years
Mean 6 SEM 56 6 2.2 59 6 4.5 37 6 2.2 50 6 2.4 43 6 4.1
Range 25–89 26–89 18–69 31–64 22–60
DAS28
Mean 6 SEM 5.0 6 0.2 4.8 6 0.3 – 4.9 6 0.3 –
Range 2.6–6.9 2.6–6.9 – 2.7–6.9 –
ESR, mm/hour
Median (IQR) 16 (9.5–33) 22 (16–37) – 18 (12–50) –
Range 2.0–75 7.0–75 – 2.0–75 –
CRP, mg/liter
Median (IQR) 6.0 (5.0–15.3) 15 (7.5–18) – 11 (5.0–30) –
Range 5.0–43 5.0240 – 5.0–64 –
Treatment, no. of patients
None 4 3 – 1 –
NSAID 2 2 – 0 –
DMARD† 33 1 – 12 –
TNF inhibitor 3 7 – 2 –
Steroids 1 0 – 0 –
RF, no. positive/no. negative 32/8 12/1 – 12/2 –
Disease duration, years
Median (IQR) 5.7 (2.3–18) 7.5 (2.0–20) – 4.0 (1.8–6.5) –
Range 0–60 0–60 – 0.5–40 –
* In these analyses, data from the peripheral blood (PB) or synovial fluid (SF) of RA patients were not available for some
of the variables, as follows: in the Treg cell frequency and phenotype assays, n 5 1 for the Disease Activity Score in 28 joints
(DAS28), n 5 2 for erythrocyte sedimentation rate (ESR), n 5 5 for C-reactive protein (CRP) level and n 5 12 with a CRP
level ,5 mg/liter, n 5 3 for rheumatoid factor (RF) status, and n 5 7 RA PB and n 5 3 RA SF for disease duration; in the
functional assays, n 5 1 for age, n 5 1 for ESR, n 5 2 for CRP level and n 5 2 with a CRP level ,5 mg/liter, n 5 1 for RF
status, and n 5 2 for disease duration. IQR 5 interquartile range; TNF 5 tumor necrosis factor.
† Disease-modifying antirheumatic drug (DMARD) use was as follows: in patients analyzed for Treg cell frequency and
phenotype, methotrexate (MTX) n 5 15, hydroxychloroquine (HCQ) n 5 3, sulfasalazine (SSZ) n 5 2, MTX/HCQ n 5 4,
MTX/SSZ n 5 2, MTX/HCQ/SSZ n 5 4, MTX/HCQ/steroid n 5 1, MTX/nonsteroidal antiinflammatory drug (NSAID)
n 5 1, and HCQ/SSZ n 5 1; in patients analyzed for Treg cell function, MTX n 5 8, SSZ n 5 1, MTX/HCQ n 5 1, MTX/
HCQ/SSZ n 5 1, and MTX/steroid n 5 1.
104 WALTER ET AL
rhea, or thyroiditis (22). These findings suggest that there
is no direct correlation between impaired Treg cell pres-
ence and/or function and the development of arthritis.
Furthermore, several groups, including our own,
have shown that Treg cells from the peripheral blood
(PB) of patients with RA are intact in their capacity to
suppress the proliferation of, or cytokine production by,
Teff cells (2,3,5,7,23,24). Moreover, in all studies except
one (14) that have investigated CD41CD251 Treg cells
in the inflamed joints of patients with arthritis, the find-
ings concur, showing that these cells are functionally
intact and are fully capable of suppressing proliferation
and cytokine production ex vivo (1–7,25–27). Instead,
the dysregulation of Teff cell function in arthritis may
be attributed to resistance of activated Teff cells to Treg
cell–mediated suppression, rather than to intrinsic
defects in Treg cell function (2,26,28–31).
Reasons for the conflicting results obtained in the
studies investigating PB-derived Treg cells in RA patients
are neither well reported nor understood, but appear to
not be simply explained by differences in cell isolation pro-
cedures or patient characteristics (for review, see ref. 32).
Interpretation of the results may, however, be restricted
by the fact that most of these earlier studies utilized only a
limited range of readout assays, often focusing on suppres-
sion of either Teff cell proliferation or cytokine production
(mostly, production of IFNg, TNF, or interleukin-17 [IL-
17]). We sought to shed light on whether PB Treg cells
are truly dysfunctional in RA by performing an extensive
analysis of CD31CD41CD251CD127low cells (hereafter
referred to as Treg cells) in both the CD45RO1 and
CD45RA1 T cell compartments, using a wide range of
readout systems. Our collective data indicate that there is
no global defect in either CD45RO1 memory Treg cells
or CD45RA1 naive Treg cells in the PB of patients with
chronic RA.
PATIENTS AND METHODS
Patients and healthy volunteers. PB and synovial
fluid (SF) samples were obtained from patients with RA
recruited from the rheumatology outpatient clinic at Guy’s and
St. Thomas’ Hospital NHS Trust (London, UK). Clinical para-
meters such as Disease Activity Score in 28 joints (DAS28)
(33), erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP) level, rheumatoid factor status, medication, age, sex, and
disease duration were documented on the day of sample collec-
tion (Table 1). Healthy control subjects were recruited from
among local staff volunteers. Written informed consent was
received from all participants. Samples were collected in com-
pliance with the Declaration of Helsinki. Ethics approval was
given by the Bromley Research Ethics Committee (approval no.
06/Q0705/20).
Cell isolation. PB mononuclear cells (PBMCs) and SF
mononuclear cells were isolated by Ficoll-Hypaque (LSM 1077;
PAA Laboratories) density-gradient centrifugation. CD141
monocytes (purity .98%) were positively selected using CD14
MicroBeads (Miltenyi Biotec). CD41 T cells were isolated from
the CD142 cell fraction by negative selection (Miltenyi Biotec)
and stained with PerCP/Cy5.5-conjugated CD4, allophycocyanin
(APC)/Cy7–conjugated CD45RA, Pacific Blue–conjugated
CD45RO, fluorescein isothiocyanate (FITC)–conjugated CD127
(BioLegend), and phycoerythrin (PE)–conjugated CD25 (Milte-
nyi Biotec). CD41CD45RA1CD45RO2CD251CD127low cells
(naive Treg cells), CD41CD45RA2CD45RO1CD251
CD127low cells (memory Treg cells), CD41CD45RA2
CD45RO1CD252CD1271 cells (CD252 memory Teff cells),
or CD41CD45RA2CD45RO1CD25intermediateCD1271 cells
(CD25int memory Teff cells) were sorted by fluorescence-
activated cell sorting (FACS) analysis using a BD FACSAria II
(.98% purity for each subset) (see Supplementary Figure 1,
available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.39408/abstract).
Phenotype and cell frequency analyses. For analyses
of phenotype and frequency of each cell subset, PE-conjugated
CD25 (Miltenyi Biotec), APC/Cy7-conjugated CD3, PerCP/
Cy5.5-conjugated CD4, PE/Cy7-conjugated CD39, Alexa Fluor
488–conjugated CD127, Alexa Fluor 647–conjugated CD161,
Pacific Blue–conjugated CD45RO, and Alexa Fluor 647–
conjugated FoxP3 (all from BioLegend) were used. For FoxP3
staining, cells were extracellularly stained, and were then fixed
and permeabilized using 13 FoxP3 Perm buffer (BioLegend).
Cells were acquired on a BD FACSCanto II and analyzed using
FlowJo software (version 7.6.1; Tree Star).
Analysis of cytokine-expressing Treg cells. Ex vivo
culture. PBMCs (2 3 106 cells/ml) were stimulated in RPMI
1640 culture medium containing 20 mM L-glutamine (Gibco),
1% penicillin–streptomycin (Gibco), and 10% fetal bovine
serum (batch no. F9665, lot no. 030M3399; Sigma) for 3 hours
with phorbol myristate acetate (PMA) (50 ng/ml; Sigma) and
ionomycin (750 ng/ml; Sigma) in the presence of GolgiStop
(BD Biosciences), in accordance with the manufacturer’s
instructions. Surface staining for PE/Cy7-conjugated CD3,
APC/Cy7-conjugated CD14 (BioLegend), and Pacific Blue–
conjugated CD45RO was followed by intracellular staining for
PerCP/Cy5.5-conjugated CD4, PE-conjugated IL-17A (BioLe-
gend), FITC-conjugated TNF (BioLegend), or Alexa Fluor
647–conjugated FoxP3.
In vitro culture. CD141 monocytes (1 3 105) were
cocultured with sorted Treg cells or Teff cells for 3 days at a 1:1
ratio in culture medium containing 100 ng/ml soluble anti-CD3
monoclonal antibodies (mAb) (OKT-3; Janssen-Cilag) in 96-
well U-bottomed culture plates at 378C in an atmosphere of 5%
CO2. When indicated, 100 ng/ml lipopolysaccharide (LPS; Sig-
ma) was added on day 0. On day 3, the cells were stimulated
with PMA/ionomycin for 6 hours, with GolgiStop present for
the last 3 hours, followed by surface staining for Pacific Blue–
conjugated CD2 (BioLegend) and APC/Cy7-conjugated CD14.
Cells were fixed with 2% paraformaldehyde and intracellularly
stained for PE-conjugated IL-17A, PerCP/Cy5.5-conjugated
IFNg, APC-conjugated TNF, and Alexa Fluor 488–conjugated
IL-10 (all from BioLegend) using 0.5% saponin.
T cell suppression assay. Freshly sorted CD252 Teff
cells (2–5 3 106/ml) or, where indicated, CD25int Teff cells were
labeled with 2 mM 5,6-carboxyfluorescein succinimidyl ester
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(CFSE; Molecular Probes) for 15 minutes at 378C. Labeled cells
(5 3 104) were cultured with sorted Treg cells at various concen-
trations (1 3 10425 3 104) and 5 3 104 monocytes, in the pres-
ence or absence of 100 ng/ml LPS, in a 96-well U-bottomed
plate. On day 3, supernatants were collected for analysis of cyto-
kine production. In addition, T cell proliferation was determined
by flow cytometry, measuring CFSE fluorescence. Results are
expressed as the percentage suppression of T cell proliferation,
Figure 1. Frequency and phenotype of CD31CD41CD45RO1CD251CD127low Treg cells in patients with rheumatoid arthritis (RA). A,
Fluorescence-activated cell sorting analysis was used to gate on CD251CD127low Treg cells (boxed area with percentage value shown) within the
CD41CD45RO1 T cell population in peripheral blood mononuclear cells (PBMCs) from RA patients (left). Percentages of these cells were com-
pared between healthy controls (HC) and RA patients (each n 5 42) (center) or between age-matched healthy controls (mean 6 SD age 49 6 2.5
years) and RA patients (mean 6 SD age 49 6 2.4 years) (each n 5 20) (right). B, Expression levels of the indicated surface markers in
CD31CD41CD45RO1CD251CD127low Treg cells were analyzed in PBMCs from healthy controls (n 5 40) and RA patients (n 5 36). FoxP3
expression was measured intracellularly (n 5 23 healthy controls, n 5 30 RA patients). C, The percentage of CD251CD127low cells within
CD41CD45RO1 T cells was determined in paired samples of freshly isolated PB and synovial fluid (SF) from RA patients (n 5 15) (top), and Treg
cell frequencies in the RA SF (n 5 10) were assessed for correlation with the Disease Activity Score in 28 joints (DAS28), by Spearman’s test (bot-
tom). Symbols represent individual patients. D, PBMCs from healthy controls (n 5 7) and RA patients (n 5 9) were stimulated with phorbol myris-
tate acetate and ionomycin for 3 hours in the presence of GolgiStop, and the percentage of interleukin-17 (IL-17)–positive or tumor necrosis factor
(TNF)–positive cells (boxed areas with percentage values shown) within CD31CD41CD142CD45RO1FoxP31 T cells was determined. Represen-
tative dot plots are shown. In A, B, and D, symbols represent individual donors; horizontal bars show the mean. Groups were compared by either
paired or unpaired t-test. MFI 5 mean fluorescence intensity.
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calculated using the following formula: (100 2 [% proliferation
with Treg cells/% proliferation without Treg cells]) 3 100.
Monocyte suppression assay. Freshly isolated CD141
monocytes (1 3 105) were cultured with or without sorted
CD41CD45RO1CD251CD127low Treg cells at a 1:1 ratio in
the presence of 100 ng/ml LPS and 100 ng/ml anti-CD3. Super-
natants were collected on day 3 for analysis by multiplex assay.
Cytokine detection. Supernatants were stored at 2808C
until analyzed by enzyme-linked immunosorbent assay (for IL-6
and IL-8; BioLegend) or by the Human Cytokine 25-plex assay
(Invitrogen Life Technologies) on the Luminex platform.
Gene expression profiling. Sorted Treg and Teff cell
samples were lysed in 500 ml of TRIzol (Invitrogen). Chloro-
form (100 ml) was added, and the samples were then whirl
mixed and incubated for 2–3 minutes at room temperature.
Following centrifugation (10,000g for 15 minutes at 4C), the
water phase was further purified using the RNeasy MinElute
Cleanup kit (Qiagen). RNA integrity was confirmed on an Agi-
lent Technologies 2100 bioanalyzer using total RNA Nano
chips. One hundred nanograms of total RNA was used to pre-
pare the targets, using the 3 0 IVT Express kit (Affymetrix) in
accordance with the manufacturer’s instructions. Hybridization
cocktails were hybridized onto a Human Genome U219 Array
plate in a GeneTitan instrument (both from Affymetrix). Chips
were scanned and gene expression data were normalized using
the RMA algorithm and Bioconductor package “Affy” (avail-
able at http://www.bioconductor.org). A custom chip definition
file (available at http://brainarray.mbni.med.umich.edu) was
used. Gene expression profiling analysis was performed using
Qlucore Omics Explorer software, version 3.0. The microarray
data have been deposited in the GEO database (GEO acces-
sion no. GSE65010).
Statistical analysis. Significance testing was per-
formed with GraphPad Prism software, version 5. Data were
tested for normality using the D’Agostino and Pearson omni-
bus normality test, followed by appropriate parametric or non-
parametric testing for significance.
RESULTS
Comparing frequencies of PB CD41CD251
CD127low Treg cells between RA patients and healthy
controls. Frequencies of CD41CD251CD127low Treg
cells (34) in the PB from patients with RA were deter-
mined within the CD31CD41CD45RO1 (memory) T
cell compartment, since CD41CD25high Treg cells are
predominantly memory cells (35) and because T cells in
the SF are of the CD45RO1 memory phenotype (36).
We found no significant differences in the percentage of
CD251CD127low Treg cells within CD41CD45RO1 T
cells between PB samples from RA patients and those
from healthy controls (each n 5 42), even when the
groups were age-matched (mean 6 SD age 49 6 2.4 years
in RA patients versus 49 6 2.5 years in healthy controls
[each n 5 20]) (Figure 1A). Treg cell frequencies did not
correlate with age in either the RA cohort or the healthy
control cohort (see Supplementary Figure 2A, available
on the Arthritis & Rheumatology web site at http://online-
library.wiley.com/doi/10.1002/art.39408/abstract). No sex-
specific differences in Treg cell frequencies were found
(results not shown). In addition, the frequencies of Treg
cells within CD31CD41CD45RO2 T cells (naive Treg
cells) were also similar between RA patients and healthy
controls (see Supplementary Figure 2B, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39408/abstract).
We investigated the ex vivo phenotype of CD251
CD127low cells within the CD31CD41CD45RO1 T cell
compartment in PBMCs from RA patients and healthy
controls. CD45RO1 Treg cells from RA patients
(n 5 36) showed similar expression levels of CD4, CD25,
and CD127 as those from healthy controls (n 5 40) (Fig-
ure 1B). We found no significant differences in the
expression levels or the percentage of cells expressing the
ectoenzyme CD39, a Treg cell–specific surface marker
(37), or CD161, which identifies a subpopulation of Treg
cells with increased potential to express the pro-
inflammatory cytokine IL-17 (38) (Figure 1B and Sup-
plementary Figure 2C, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.39408/abstract). A small increase in
FoxP3 expression was observed in CD45RO1 Treg cells
from RA patients (Figure 1B). The phenotype of
CD45RO2 Treg cells from RA PB showed a very similar
pattern as that seen in CD45RO1 Treg cells and was not
different from healthy control CD45RO2 Treg cells (see
Supplementary Figures 2C and D, available on the Arth-
ritis & Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.39408/abstract).
Interestingly, when Treg cells were analyzed in
paired PB and SF samples from patients with RA, we
observed an increase in the frequency of CD45RO1
memory Treg cells in the SF compared to the PB, and this
finding showed a positive correlation with the DAS28
(Spearman’s r 5 0.7988, P 5 0.0072; n 5 10) (Figure 1C).
In contrast, the frequency of CD45RO1 Treg cells in the
PB did not correlate with the DAS28 (Spearman’s
r 5 0.02, P 5 0.9; n 5 41) (results not shown).
Taken together, these data indicate that both the
frequency and phenotype of naive and memory Treg cells
in the PB were similar between RA patients and healthy
controls. Memory Treg cells were, however, increased at
the site of inflammation, i.e., in the SF relative to the PB,
in patients with RA, and the frequency of synovial Treg
cells correlated positively with the level of disease activity.
Cytokine profiles of PB Treg cells from RA
patients and healthy controls. We investigated whether
PB-derived Treg cells in RA patients showed a more
proinflammatory cytokine profile, by determining the per-
centages of IL-17– and TNF-expressing Treg cells ex vivo.
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Figure 2. Ability of CD45RO1 Treg cells from patients with RA to suppress Teff cell proliferation and cytokine production.
CD41CD45RA2CD45RO1CD252CD1271 Teff cells from healthy controls and RA patients were labeled with 5,6-carboxyfluorescein succini-
midyl ester (CFSE) and cocultured with CD141 monocytes at a 1:1 cell ratio in the presence of anti-CD3 monoclonal antibody (100 ng/ml), in the
absence or presence of autologous sorted CD45RO1 Treg cells (added at the indicated Teff cell:Treg cell ratios). On day 3, cell proliferation was
assessed by flow cytometry (A and B), and cell culture supernatants were collected for detection of secretion of interferon-g (IFNg) (C) and TNF
(D) by Luminex. A, Histograms show the CFSE dilution and the percentage of cell proliferation at the different cell ratios in representative samples
from a healthy control subject and an RA patient. B–D, Left, Cumulative data show the percentage of proliferating cells (B) or levels of cytokines
(C and D) in the absence or presence of Treg cells from healthy controls (n 5 8) and patients with RA (n 5 8–9). Right, The percentage suppres-
sion of Teff cell proliferation is shown for each Teff cell:Treg cell ratio. Bars show the mean 6 SEM. The broken horizontal line in C and D indi-
cates the lower limit of detection. Statistical analysis was performed using Kruskal-Wallis test with Dunn’s multiple comparison test. * 5 P , 0.05;
** 5 P , 0.01; *** 5 P , 0.001 versus absence of Treg cells. NS 5 not significant (see Figure 1 for other definitions).
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We focused on memory Treg cells, since this population is
more plastic compared to the naive Treg cell population
(39). No significant differences in the percentages of IL-
171 or TNF1 cells within the CD31CD41CD45RO1
FoxP31 T cell population were found between PB sam-
ples from RA patients and those from healthy controls
(Figure 1D).
To investigate whether CD45RO1 Treg cells
from RA patients would show increased cytokine
expression following in vitro culture with CD141 mono-
cytes, CD45RO1 Treg cells were sorted from the PB of
RA patients (n 5 13) and healthy controls (n 5 10) and
cultured in vitro with autologous CD141 monocytes (at
a 1:1 ratio) in the presence of anti-CD3 mAb. No signifi-
cant differences in the percentages of cytokine-
expressing Treg cells (expressing IL-17, IFNg, TNF, or
IL-10) were observed between RA patients and healthy
controls (see Supplementary Figure 3A, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39408/abstract).
We recently showed that LPS stimulation of
CD141 monocytes results in increased secretion of IL-
1b, IL-6, and TNF by the monocytes, which thereby
drives the expression of IL-17 by Treg cells (8). How-
ever, the addition of LPS to the above cultures did not
reveal an increased propensity of Treg cells from RA
patients to express the proinflammatory cytokines IL-
17, IFNg, or TNF as compared to Treg cells from
healthy controls (see Supplementary Figure 3B, avail-
able on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.39408/abstract).
Taken together, these data indicate that CD45RO1
memory Treg cells in the PB of patients with RA do not
show an enhanced potential to produce proinflamma-
tory cytokines.
Treg cell suppression of T cell proliferation, as
well as IFNg and TNF secretion, in autologous Teff
cell–monocyte cocultures from patients with RA. We
next investigated whether CD45RO1 Treg cells from RA
patients are capable of suppressing the proliferation of
Teff cells. CD45RA2CD45RO1 Treg cells were sorted
from the PB of RA patients (n 5 9) and healthy controls
(n 5 8). Autologous FACS-sorted CD41CD45RA2
CD45RO1CD252CD1271 cells (Teff cells) were la-
beled with CFSE and cocultured with autologous mono-
cytes (at a 1:1 ratio) in the presence of anti-CD3 mAb.
CD45RO1 Treg cells were added to the cultures at 3 dif-
ferent cell ratios (as indicated in Figures 2A–D), and Teff
cell proliferation was assessed on day 3 by gating on
CFSE1 Teff cells. The presence of CD45RO1 Treg
cells, both from RA patients and from healthy controls,
led to a cell ratio–dependent reduction in the prolifera-
tion of autologous Teff cells (Figures 2A and B).
Although in cocultures at the 1:0.5 and 1:1 cell ratios, the
mean percentage of Treg cell–mediated suppression was
slightly lower in RA PB, this was not significantly different
from that in healthy control PB (Figure 2B). The addition
of LPS during coculture, to mimic a proinflammatory
environment, did not abrogate Treg cell–mediated sup-
pression of Teff cell proliferation in either RA patients or
healthy controls (results not shown).
CD45RO1 Treg cells from RA patients were
also capable of suppressing the secretion of IFNg and
TNF in these cocultures (Figures 2C and D). Treg cells
from some patients appeared to be less efficient in sup-
pressing cytokine secretion, especially at the lower cell
ratio (1:0.5); however, the level of suppression was not
significantly different from that mediated by Treg cells
from healthy controls. IL-17 secretion was not detect-
able in any of the conditions.
Interestingly, patients whose PB samples showed
less efficient Treg cell–mediated suppression of Teff
cell proliferation were not necessarily those whose
PB samples showed less efficient suppression of cyto-
kine production (e.g., RA patient 5 in Supplementary
Table 1, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.39408/abstract). Furthermore, less efficient Treg
cell–mediated suppression of Teff cell proliferation could
also be observed in the PB of certain healthy control sub-
jects (e.g., healthy controls 5 and 6 in Supplementary
Table 1). We did not find an association between clinical
parameters (DAS28, CRP level, ESR, disease duration)
and the ability of Treg cells from RA patients to suppress
proliferation. Notably, Treg cells from the patient with the
highest DAS28 were among the better suppressors (see
RA patient 9 in Supplementary Table 1).
It was shown that in patients with multiple sclero-
sis, a functional defect resides within naive Treg cells
(40,41). We found that CD45RA1 Treg cells from both
RA patients and healthy controls suppressed less effi-
ciently than did their CD45RO1 Treg cell counterparts.
However, the overall ability of CD45RA1 Treg cells to
suppress CD45RO1 Teff cell proliferation (at a 1:1 ratio
of Teff cells to Treg cells) was not significantly different
between RA patients (mean 6 SD 21 6 8% suppression;
n 5 7) and healthy controls (33 6 8% suppression; n 5 6)
(P 5 0.37) (see Supplementary Table 1).
Recently, it was shown that the ability of Treg
cells to suppress proliferation of Teff cells with inter-
mediate CD25 expression (CD25int Teff cells) was
reduced compared to their ability to suppress prolifera-
tion of CD252 Teff cells. This could be attributed to a
more activated phenotype and higher proliferation rate
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of CD25int Teff cells (42). We found that the frequencies
of CD25int Teff cells were similar between the PB of RA
patients and the PB of healthy controls (Figure 3A). In
both RA patients and healthy controls, CD25int Teff cells,
compared to CD252 Teff cells, contained higher percen-
tages of IL-17–expressing and TNF-expressing cells fol-
lowing stimulation (Figure 3B), indicating that the
CD25int Teff cell population may contain more activated
Figure 3. Ability of CD45RO1 Treg cells from patients with RA to suppress CD25intermediate (CD25int) Teff cell proliferation and cytokine
production. A, The percentage of CD25intCD1271 and CD252CD1271 Teff cells within CD41CD45RO1 T cells was determined in PB sam-
ples from healthy controls (n 5 12) and RA patients (n 5 16). Symbols represent individual donors; horizontal bars show the mean. Groups were
compared by unpaired t-test. B, CD252CD1271 and CD25intCD1271 Teff cells were sorted from CD41CD45RO1 T cells in the PB of healthy
controls (n 5 7) and RA patients (n 5 9) and cocultured with autologous monocytes in the presence of anti-CD3. The percentages of Teff cells
producing IL-17 or TNF were determined following restimulation of the cells with phorbol myristate acetate and ionomycin on day 3. Data were
analyzed by Wilcoxon’s matched pairs signed rank test. C, CD41CD45RA2CD45RO1CD25intCD1271 Teff cells from healthy controls and RA
patients were labeled with 5,6-carboxyfluorescein succinimidyl ester and cocultured with CD141 monocytes at a 1:1 cell ratio in the presence of
anti-CD3 monoclonal antibody (100 ng/ml), in the absence or presence of autologous sorted CD45RO1CD251CD127low Treg cells (added at
the indicated Teff cell:Treg cell ratios). On day 3, Teff cell proliferation was assessed by flow cytometry. Left, Cumulative data show the percent-
age of proliferating cells in the absence or presence of Treg cells from healthy controls (n 5 6) and RA patients (n 5 4). Right, The percentage
suppression of Teff cell proliferation is shown for each Teff cell:Treg cell ratio. Bars show the mean 6 SEM. Data were analyzed by Mann-
Whitney test. NS 5 not significant (see Figure 1 for other definitions).
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cells. Treg cells from RA patients were, however, able to
effectively suppress the proliferation of autologous
CD25int Teff cells, similar to the findings in healthy con-
trols (Figure 3C). Taken together, these data show there
is no significant difference in the ability of Treg cells to
suppress autologous Teff cell proliferation or the secre-
tion of IFNg or TNF in monocyte–T cell cocultures from
the PB of RA patients compared to that from healthy
controls.
Suppression of monocyte-derived cytokines and
chemokines by Treg cells from RA patients. We re-
cently demonstrated that CD141 PB-derived monocytes
from RA patients show a more activated phenotype com-
pared to PB monocytes from healthy controls (8). We
therefore investigated the ability of Treg cells from RA
patients to suppress LPS-induced monocyte-derived cyto-
kine and chemokine production. PB monocytes from RA
patients (n 5 9) and healthy controls (n 5 8) were cul-
tured with LPS in the absence or presence of autologous
CD45RO1 Treg cells for 3 days. LPS-activated PB
monocytes from RA patients and those from healthy con-
trols produced similar levels of cytokines/chemokines in
the absence of Treg cells (Figure 4). In the presence of
Treg cells, although considerable interdonor differences
were observed, similar overall levels of suppression were
found in the majority of RA patients and healthy controls
with regard to suppression of IL-6, IL-8/CXCL8, IL-12,
IL-15, IFNg-inducible protein 10/CXCL10, RANTES/
CCL5, and TNF. Although a lack of suppression of
individual cytokines/chemokines was observed in some
patients (e.g., IL-8 in a patient with RA [open downward
triangles in Figure 4]), Treg cells from these same
Figure 4. Ability of CD45RO1 Treg cells from patients with RA to suppress lipopolysaccharide (LPS)–induced monocyte (Mono)–derived cytokine/
chemokine production. CD141 monocytes from healthy controls (n 5 6–8) and RA patients (n 5 7–9) were cultured in the presence of 100 ng/ml
LPS without or with sorted CD45RO1 Treg cells at a 1:1 ratio. After 3 days, the supernatants were collected and analyzed using a human 25-plex
cytokine array or by enzyme-linked immunosorbent assay (for IL-6 and IL-8). Each line joined by symbols represents an individual donor. The broken
horizontal line indicates the lower limit of detection. For monocyte chemotactic protein 1 (MCP-1), the dotted horizontal line indicates the upper limit
of detection. Data were analyzed by Wilcoxon’s matched pairs signed rank test. * 5 P , 0.05; ** 5 P , 0.01 versus absence of Treg cells. IL-
1Ra 5 interleukin-1 receptor antagonist; IP-10 5 interferon-g–inducible protein 10; MIP-1a 5 macrophage inflammatory protein 1a; NS 5 not signifi-
cant (see Figure 1 for other definitions).
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Figure 5. Gene expression profiling of CD45RA1 and CD45RO1 Treg and Teff CD41 T cell subsets from the peripheral blood (PB) of healthy
controls (HC) and patients with rheumatoid arthritis (RA). CD251CD127low Treg cells and CD252CD1271 Teff cells were sorted from the
CD45RA1CD45RO2 (naive) or CD45RA2CD45RO1 (memory) CD41 T cell compartments from the PB of age- and sex-matched healthy con-
trols (mean age 54 years [range 34–69]) and RA patients (mean age 57 years [range 37–75]) (each n 5 6 female donors). Five of the RA patients
were receiving disease-modifying antirheumatic drug treatment (n 5 3 methotrexate [MTX], n 5 1 hydroxychloroquine [HCQ], n 5 1 MTX, HCQ,
and sulfasalazine); 1 patient had received no medication. All patients had moderate-to-active disease, with a mean 6 SEM Disease Activity Score in
28 joints of 4.8 6 0.3. A, Principal components analysis (PCA) based on global gene expression levels in the PB shows distinct clusters of the
CD45RA1 Teff, CD45RA1 Treg, CD45RO1 Teff, and CD45RO1 Treg cell populations. B, PCA shows that the 4 T cell populations do not clus-
ter differently between healthy controls and RA patients. C, The heatmap, representing results from hierarchical cluster analysis, shows the relative
expression levels of previously described Treg signature–associated genes in the different T cell subsets from the PB of healthy controls and RA
patients.
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patients efficiently suppressed the other cytokines/
chemokines.
More notable differences were observed with
regard to Treg cell suppression of IL-1b, IL-1 receptor
antagonist (IL-1Ra), IL-7, macrophage inflammatory
protein 1a (MIP-1a)/CCL3, and MIP-1b/CCL4, which
were suppressed by CD45RO1 Treg cells from healthy
controls, whereas this was not consistently observed in
cultures with Treg cells from RA patients (Figure 4 and
Supplementary Table 2, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.39408/abstract). However, again this was
not a global defect, as PB samples from ;44% of the
RA patients did show an intact ability to suppress these
chemokines and cytokines. Monocyte chemotactic pro-
tein 1 was not significantly suppressed by Treg cells
from either RA patients or healthy controls, and IL-10
was mostly increased in the presence of Treg cells both
from RA patients and from healthy controls, as has been
previously shown in healthy individuals (43). Taken
together, these data indicate that some differences can be
observed in the capacity of Treg cells from RA patients
to suppress secretion of certain cytokines/chemokines by
LPS-activated monocytes. However, this impairment was
not detected for all cytokines/chemokines and, further-
more, was not observed in all patients.
Gene expression profiles of PB CD45RA1 and
CD45RO1 Treg cells and Teff cells from RA patients
and healthy controls. Finally, we assessed whether
Treg cells from RA patients are different at a molecular
level, using genome-wide gene expression profiling of
FACS-sorted PB-derived Treg cells from the CD45RA1
CD45RO2 (naive) and CD45RO1CD45RA2 (memory)
T cell compartments from the PB of RA patients and
healthy controls. CD45RA1 and CD45RO1 Teff cells
were isolated in parallel. As shown by principal components
analysis, each of the 4 CD41 T cell subsets was found to be
grouped as a distinct cluster based on global messenger
RNA expression levels (Figure 5A). However, cells from
RA patients did not cluster separately from cells derived
from healthy controls, within either the Treg cell or Teff
cell populations (Figure 5B). In fact, no significant differen-
tially expressed genes were found when comparing RA cells
and healthy control cells in any of the 4 populations (false
discovery rate 5%, fold change in gene expression 1.5).
To verify that the sorted Treg cells were truly of
a regulatory cell type, we investigated the relative
expression levels of genes previously associated with a
Treg cell phenotype (44). As visualized in the heatmap
shown in Figure 5C, CD45RO1 Treg cells as well as
CD45RA1 Treg cells could be clearly distinguished
from their Teff cell counterparts based on the expres-
sion of well-described Treg signature genes, including
expression of FOXP3, CTLA4, CD25, CD27, and CD127
(Figure 5C). In summary, the ex vivo gene expression
profiles of Treg cells from the PB of RA patients and
healthy controls were highly similar, supporting the
other observations made herein showing that Treg cells
in the PB of RA patients are not intrinsically different
from those in the PB of healthy individuals.
DISCUSSION
In this report we have presented a comprehen-
sive analysis of the frequency, phenotype, cytokine pro-
file, suppressive potential, and gene expression profile
of CD41CD251CD127low Treg cells from both the
CD45RO1 and CD45RA1 T cell compartments of the
PB from patients with established RA compared to age-
and sex-matched healthy individuals. Collectively, our
findings indicate that CD41CD251CD127low Treg cells
in the blood of patients with chronic RA are not intrinsi-
cally or globally defective.
We show that PB Treg cell frequencies are simi-
lar in RA patients and healthy controls in both the
CD45RO1 and CD45RO2 T cell compartments, thus
extending the findings from previous studies (1,3,4,17).
Consistent with the results reported in earlier studies
(1–8,25), we found that the percentages of CD45RO1
Treg cells were significantly increased in the RA SF
compared to paired RA PB samples, and notably, this
positively correlated with the DAS28. Phenotypically,
PB Treg cells showed similar expression levels of CD4,
CD25, CD127, CD39, and CD161 in RA patients and
healthy controls, with a slight, but significantly, in-
creased expression of FoxP3 in RA patients, both in
CD45RO1 Treg cells and in CD45RO2 Treg cells.
Recent data indicate that Treg cells, particularly
those with a memory phenotype, can convert into IL-
171 Treg cells under proinflammatory conditions (for
review, see ref. 45). However, our data showed that
CD45RO1 Treg cells from RA patients did not contain
significantly enhanced percentages of IL-171, IFNg1, or
TNF1 cells, when analyzed ex vivo or after in vitro cul-
ture. Although some groups have reported that Treg cells
from the blood of RA patients are unable to suppress
Teff cell proliferation (14,15,17), the majority of studies
reporting on the suppressive function of PB-derived Treg
cells in RA have demonstrated intact Treg cell function
when the suppression of Teff cell proliferation was
assessed (2,5,7,13,23,24). Consistent with these observa-
tions, our findings also indicated that in RA patients, PB-
derived Treg cells from either the CD45RO1 or the
CD45RA1 T cell compartment were functionally intact
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with regard to suppression of Teff cell proliferation. In
addition, we demonstrated that Treg cells from RA
patients can suppress proliferation of both CD252 and
CD25int Teff cells to a similar extent as healthy control
Treg cells, even though CD25int Teff cells contained
increased percentages of IL-171 and TNF1 cells, sug-
gesting a potentially higher activation status of these cells.
Several groups have reported that in RA, PB-
derived Treg cells are defective in their ability to sup-
press IFNg and/or TNF production (13–17), whereas
others have reported that Treg cells have intact suppres-
sive function (2,3,7). Our current data indicate that the
ability of Treg cells from the blood of RA patients to
suppress these cytokines is not significantly impaired. It
has been suggested that Treg cells from RA patients are
impaired in their ability to suppress IL-17 (18,46). In
our assays, IL-17 levels were below the limit of detec-
tion. Analysis of the ability of Treg cells to suppress
monocyte-derived cytokines/chemokines revealed no
consistent differences between RA patients and healthy
controls with regard to the suppression of TNF, IL-6,
IL-8, IL-12, IL-15, and CCL5, although suppression
seemed reduced in some patients. We did find impaired
suppression of IL-1b, IL-1Ra, IL-7, CCL3, and CCL4 in
RA PB relative to healthy control PB; however, this was
not consistently observed in all patients. Importantly,
none of the patients displayed impairment in all tested
aspects of Treg cell–mediated suppression. Additionally,
in healthy controls, some degree of variation in Treg cell
suppressive function was observed.
Findings in a recent study suggested that Treg cell
suppressive function (defined by suppression of T cell
proliferation and IFNg production) was defective in
patients with early, active RA who had not yet received
therapy (treatment-naive), whereas Treg cell suppressive
function was not defective in patients with chronic RA
who had been exposed to methotrexate (MTX), although
the group numbers were small (n 5 4 per study group)
(47). Another recent study in patients with RA suggested
that Treg cell function was reduced in MTX nonrespond-
ers, and that this defect was related to low CD39 expres-
sion (48). The identification of intact peripheral Treg cell
function in patients with chronic RA who had received
therapy with disease-modifying antirheumatic drugs
(DMARDs)/biologic drugs, as described herein and in
previous studies (2,7,23,24), could thus be a consequence
of effective DMARD therapy. However, other studies
have shown no defects in the suppressive capacity of
CD41CD25high Treg cells from patients with early, active
RA who were being treated with steroids and were
DMARD-naive, as compared to patients who were being
treated with DMARDs and had well-controlled disease
or healthy controls (5,7). In our study, none of the
patients had early RA or were treatment-naive, and
therefore further studies are required before conclusive
statements can be made regarding Treg cell function in
treatment-naive patients with early RA. Nonetheless, the
notion that DMARD or biologic therapy may restore
defective Treg cell function is important to consider.
It is also possible that disease activity influences
Treg cell function. However, when we compared the
results with regard to suppression of IFNg and TNF pro-
duction and T cell proliferation between those patients
with highly active disease (DAS28 .5.1; n 5 4) and those
with moderate disease activity (DAS28 3.2–5.1; n 5 4)
(see Supplementary Table 1), we observed neither consid-
erable differences nor consistent differences between
these 2 groups with respect to Treg cell function. This
finding clearly indicates that even in patients with active
disease, Treg cells are still functional. Taken together with
our finding that Treg cells are increased in the inflamed
joint and this is correlated with the DAS28, it is reasonable
to suggest that Treg cell activity is preserved, and may
even be enhanced (8), during inflammation in chronic
RA, as a means to dampen collateral damage. This is sup-
ported by experimental models showing that Treg cells are
increased in number and function during inflammation
(49) and that TNF can boost Treg cell function (50).
The notion that PB-derived Treg cells are not
defective in patients with chronic RA is strengthened by
our findings that neither CD45RA1 nor CD45RO1
Treg cells displayed significantly differentially expressed
genes relative to their counterparts from the PB of sex-
and age-matched healthy controls. One limitation of in
vitro suppression assays is that cells are taken out of their
inflammatory environment when tested for suppressive
activity. Our genome-wide expression arrays were per-
formed on cells that were isolated from patients directly
ex vivo, thus closely resembling the in vivo situation. An
interesting side observation from our work was that a
large proportion of Treg signature genes are predomi-
nantly expressed in CD45RO1, but not CD45RA1,
Treg cells, suggesting that current investigations of Treg
cell–specific signature genes may be biased toward fea-
tures of the memory Treg cell population.
Importantly, our findings do not exclude the prob-
ability that cues from the local inflammatory environment
can impede Treg cell–mediated suppression. Indeed,
inflammatory cytokines like IL-6 and TNF can negatively
modulate FoxP3 activity (14,51). A recent study showed
that PB-derived Treg cells from RA patients were unable
to suppress Teff cell proliferation or TNF or IFNg secre-
tion by autologous PB Teff cells, and this was attributed to
the increased resistance of Teff cells to Treg cell–mediated
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suppression, rather than to defective Treg cell function
(31). Increased resistance of Teff cells to regulation was
also reported in a spontaneous experimental arthritis
model (49). Furthermore, using crossover experiments, it
was shown that activated T cells from the inflamed joints of
patients with RA were more resistant to Treg cell–mediated
suppression than their PB counterparts (2,26,28–30).
Collectively, our data indicate that Treg cells
from the PB of patients with chronic RA are not intrin-
sically different from those in healthy individuals. Com-
bined with previous studies showing intact suppressive
function of Treg cells derived from the inflamed joint
(1–7,25–27), these findings imply that persistent disease
activity in chronic RA cannot simply be attributed to
defective CD41CD251CD127low Treg cell function in
the circulation.
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